The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1beta/IL-17A axis
At this time, available research does not demonstrate that BPC-157 directly increases or decreases testosterone levels in healthy men
Patients with active or chronic infections should not be treated with TNF inhibitors
So are injectable peptides the real deal for skin longevity